Drug Review · us
After a 9–3 Vote Against, Capricor Presses On Through FDA Review
The Duchenne cell therapy deramiocel preserved some upper-limb function in a Phase 3 trial but failed to convince experts that evidence of efficacy against cardiomyopathy was sufficient; a statistical correction and manufacturing inspection add further uncertainty to the final decision.
For patients with advanced Duchenne muscular dystrophy, arm function determines their ability to eat, groom themselves, and operate assistive devices, while progressively worsening cardiomyopathy can threaten their lives. Capricor Therapeutics hopes its cell therapy deramiocel can slow both types of damage, but in the final stretch of the U.S. marketing review process, a difficult-to-ignore gap has emerged between the clinical results and the legally defined indication.
On July 29, the U.S. Food and Drug Administration’s (FDA) Cellular, Tissue, and Gene Therapies Advisory Committee voted 9–3 that Capricor had not yet presented substantial evidence of efficacy sufficient to support deramiocel for treating Duchenne-related cardiomyopathy. The voting question concerned only the cardiac indication, not overall disease progression; the experts’ recommendation is also not legally binding, and the FDA is still reviewing the biologics license application.
deramiocel is made from allogeneic cells derived from the heart tissue of healthy donors. It is not designed to repair the specific genetic mutations that cause Duchenne, but instead uses cellular signaling to regulate inflammation and fibrosis. This strategy, which is not limited by mutation type, could theoretically act on both skeletal muscle and cardiac muscle, but credible and clinically meaningful effects must also be demonstrated separately for the two organ systems.
The Phase 3 HOPE-3 trial supporting the application enrolled 106 patients with advanced disease, who were randomly assigned to receive infusions of deramiocel or placebo once every three months for 12 months. Results published in The Lancet showed less decline in upper-limb function in the treatment group, while some measures of cardiac function and imaging markers of myocardial scarring also favored treatment; there were no deaths during the trial, and serious adverse events were uncommon.
However, statistical success in upper-limb function cannot directly answer whether the cardiomyopathy indication is supported. In its latest update, Capricor also disclosed that a cardiac analysis had been corrected. Until the correction, the magnitude of the effect, and their relationship to the prespecified analysis method are fully clarified, publication in a journal is not in itself sufficient to dispel the FDA’s concerns about the evidence of cardiac efficacy.
Regulatory risk also extends beyond statistical methods. The company said an FDA inspection resulted in one Form 483 observation, which it continues to address. A Form 483 records conditions that inspectors believe may not comply with regulations; it is not a final enforcement or rejection decision. For a living-cell product, however, manufacturing consistency, quality control, and commercial production capability are all important parts of the approval review.
Capricor said the FDA is still reviewing the application and discussing potential paths for further submissions with the company. This could lead to additional filings and an extended review timeline, or it could end in approval or another rejection. The advisory committee’s negative vote does not predetermine the outcome, but it clearly marks the threshold: Capricor must not only show that patients’ functional decline is slowing, but also convince regulators that the cardiac benefits can withstand scrutiny of both the statistics and manufacturing quality.